Predicted protein targets (top 20)
| gene | UniProt | supporting neighbours | confidence | |
|---|---|---|---|---|
| ▸ | ALDH1A1 | P00352 | 2/20 | 0.52 |
| ▸ | SMN1; SMN2 | Q16637 | 2/20 | 0.52 |
| ▸ | POLB | P06746 | 1/20 | 0.52 |
| ▸ | MEN1 | O00255 | 1/20 | 0.50 |
| ▸ | KMT2A | Q03164 | 1/20 | 0.50 |
| ▸ | CA3 | P07451 | 2/20 | 0.45 |
| ▸ | CA5A | P35218 | 2/20 | 0.45 |
| ▸ | CA5B | Q9Y2D0 | 2/20 | 0.45 |
| ▸ | CA2 | P00918 | 2/20 | 0.45 |
| ▸ | CA14 | Q9ULX7 | 2/20 | 0.45 |
| ▸ | CA12 | O43570 | 1/20 | 0.45 |
| ▸ | CA4 | P22748 | 1/20 | 0.45 |
| ▸ | CA6 | P23280 | 1/20 | 0.45 |
| ▸ | CA7 | P43166 | 1/20 | 0.45 |
| ▸ | CA9 | Q16790 | 1/20 | 0.45 |
| ▸ | EPHX1 | P07099 | 1/20 | 0.42 |
| ▸ | PGK1 | P00558 | 2/20 | 0.33 |
| ▸ | PGK2 | P07205 | 2/20 | 0.33 |
| ▸ | MAOA | P21397 | 2/20 | 0.31 |
| ▸ | MAOB | P27338 | 2/20 | 0.31 |
Click a target to see other patent compounds predicted against it — the reverse direction, in place.
Similar compounds — the chemically nearest patent molecules
Nearest neighbours by Morgan-fingerprint cosine across the patent-compound collection, with each neighbour's top predicted target and the predicted targets it shares with this molecule.
| Compound | similarity | top predicted | shared targets | |
|---|---|---|---|---|
| SCHEMBL23366306 | 0.79 | ALDH1A1 (0.56) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL6029250 | 0.78 | PKM (0.42) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL1460181 | 0.77 | ALDH1A1 (0.54) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL7771469 | 0.76 | ALDH1A1 (0.60) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL865926 | 0.76 | — | — | |
| SCHEMBL3869183 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL5544499 | 0.75 | MAOA (0.38) | SMN1; SMN2POLBCA2CA14CA7 | |
| SCHEMBL7771621 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL22092385 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A | |
| SCHEMBL9138159 | 0.75 | ALDH1A1 (0.52) | ALDH1A1SMN1; SMN2POLBMEN1KMT2A |
Similarity is cosine over the 2,048-bit Morgan fingerprint (≈ Tanimoto). Identical fingerprints score 1.00.
Patent provenance — the patents this molecule appears in, and who filed them
Claimed or disclosed in 60 patents — showing the first 20. claimed = in the patent's claims; disclosed = body only.
| Patent | Title | Assignee | Published | Priority | Filing | Country | Status |
|---|---|---|---|---|---|---|---|
| EP-2670750-B1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR | FIBROGEN INC (US) | 2016-09-14 | — | — | EP | claimed |
| US-9271970-B2 | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FIBROGEN, INC. (US) | 2016-03-01 | — | — | US | claimed |
| US-20150174110-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. | 2015-06-25 | — | — | US | claimed |
| US-8921389-B2 | Naphthyridine derivatives as inhibitors of hypoxia inducible factor (HIF) hydroxylase | FIBROGEN, INC. (US) | 2014-12-30 | — | — | US | claimed |
| US-20140088101-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2014-03-27 | — | — | US | claimed |
| EP-2670750-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | Fibrogen, Inc. (US) | 2013-12-11 | — | — | EP | claimed |
| WO-2012106472-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | FIBROGEN, INC. (US) | 2012-08-09 | — | — | WO | claimed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | claimed |
| CN-117964684-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| CN-117964683-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2024-05-03 | — | — | CN | disclosed |
| EP-2952587-B1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC (US) | 2023-07-05 | — | — | EP | disclosed |
| CN-112867706-A | MASP-2 inhibitors and methods of use | 奥默罗斯公司 | 2021-05-28 | — | — | CN | disclosed |
| US-20180334729-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2018-11-22 | — | — | US | disclosed |
| EP-2987864-B1 | METHOD FOR DETECTING AN ANALYTE | STRATOS GENOMICS INC (US) | 2018-04-25 | — | — | EP | disclosed |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | Roche Sequencing Solutions, Inc. | 2009-02-05 | — | — | US | disclosed |
| WO-2008157696-A2 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | STRATOS GENOMICS INC. (US) | 2008-12-24 | — | — | WO | disclosed |
| US-20080166359-A1 | Methods of using MEK inhibitors | EXELIXIS, INC. | 2008-07-10 | — | — | US | disclosed |
| EP-0765879-B1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO CO (JP) | 2001-02-14 | — | — | EP | disclosed |
| US-5861429-A | MITICIDES AND ANTHELMINTICS | SANKYO COMPANY, LIMITED (JP) | 1999-01-19 | — | — | US | disclosed |
| EP-0765879-A1 | 13-Substituted milbemycin 5-oxime derivatives, their preparation and their use against insects and other pests | SANKYO COMPANY LIMITED (JP) | 1997-04-02 | — | — | EP | disclosed |
Patent text — is the patent's own abstract consistent with the prediction?
For each of this compound's patents that has machine-readable text (4 of them — usually the abstract, not the full specification), we ask MedCPT which protein the text reads most about, and where the chemistry-predicted target lands among 4885 human targets. A high rank means the patent's own wording is consistent with the prediction — a weak, independent signal, not proof of activity.
| Patent | Title | Text reads most about | Predicted target · text-rank |
|---|---|---|---|
| US-20150174110-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | ALDH1A1 660/4885SMN1; SMN2 4317/4885POLB 496/4885 |
| US-20140088101-A1 | NAPHTHYRIDINE DERIVATIVES AS INHIBITORS OF HYPOXIA INDUCIBLE FACTOR (HIF) HYDROXYLASE | HIF1AN, HIF1A, EGLN2 | ALDH1A1 660/4885SMN1; SMN2 4317/4885POLB 496/4885 |
| US-20090035777-A1 | HIGH THROUGHPUT NUCLEIC ACID SEQUENCING BY EXPANSION | ERCC4, NUDT21, CPSF6 | ALDH1A1 4129/4885SMN1; SMN2 1392/4885POLB 137/4885 |
| US-20080166359-A1 | Methods of using MEK inhibitors | BRAF, NRAS, KRAS | ALDH1A1 1438/4885SMN1; SMN2 3846/4885POLB 1676/4885 |
“Text reads most about” is the patent abstract's nearest protein in MedCPT space (background-debiased). Only ~1.4% of patents have machine-readable text, so most compounds won't have this panel.